Gynica
Gynica is an Israeli clinical-stage biotech developing cannabis-based intra-vaginal therapeutics for endometriosis via its proprietary IntraVag© microencapsulation platform. It is advancing two drug candidates (IntraVagS301 and IntraVagS302) through clinical trials and distributes a CBD product line in Israel.
- Company typePrivate
- Founded2017
- HeadquartersJerusalem, Israel
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Gynica does
Gynica is an Israeli clinical-stage biotechnology company founded in 2017 that develops cannabinoid-based therapeutic solutions for women's health, with a primary focus on endometriosis—a condition affecting approximately 190 million women and girls globally (about 1 in 10 women worldwide, including an estimated 7 million in the United States) for which current standard-of-care options (anti-inflammatory drugs, hormone therapy, surgery) often produce adverse side effects and inadequate symptom relief. The company's core technology is its proprietary IntraVag© microencapsulation platform, designed for controlled-release of active pharmaceutical ingredients directly to the vaginal cavity, enabling localized delivery of cannabinoids to minimize systemic absorption while targeting the endocannabinoid system to address endocannabinoid deficiency theorized to underlie endometriosis pathology.
Gynica is developing two drug candidates—IntraVagS301 and IntraVagS302—as intra-vaginal therapies for endometriosis symptoms, with clinical trials launched in March 2024. Beyond prescription drug development, the company operates a CBD consumer product line distributed in Israel through a partnership with Altman Health, the country's market leader for OTC and supplements. Revenue from the pharmaceutical pipeline is contingent on regulatory approval and has not yet been generated; the near-term commercial activity depends on CBD distribution. The company maintains a lean operating footprint of 1-10 employees and is headquartered at 82 Levi Eshkol Blvd., Tel Aviv, Israel.
Gynica's competitive positioning is built on a network of strategic partnerships: Lumir Lab (R&D, anchored at Hebrew University, led by Prof. Lumir Ondrej Hanus who isolated active cannabinoid compounds in 1992), Strainprint Technologies (Canadian clinical data infrastructure and proprietary digital research platform), Tikun-Olam Cannbit (pharmaceutical strategic capital), Altman Health (Israel distribution), Hempstreet (India market expansion), and PQE Group's CEO Gilda D'Incerti on the advisory board (pharmaceutical regulatory expertise). The company participates in scientific forums such as University of Oxford's Women's Health AIMday 2022 and has been covered in Reuters, Clinical Trials Arena, Labiotech, Femtech World, and Hadassah Magazine. Its go-to-market combines event-driven scientific positioning, strategic media coverage, B2B distribution partnerships, and a small social media presence on Instagram and Facebook.
Gynica firmographics
Firmographics- Name
- Gynica
- Legal name
- Gynica
- Website
- https://gynica.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Gynica is an Israeli clinical-stage biotech developing cannabis-based intra-vaginal therapeutics for endometriosis via its proprietary IntraVag© microencapsulation platform. It is advancing two drug candidates (IntraVagS301 and IntraVagS302) through clinical trials and distributes a CBD product line in Israel.
- Ownership category
- akta.pro rank
Gynica industry classification
Industry- Product category
- Women's Health Biotechnology
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Women’s Health & Reproductive Specialty Pharmaceuticals (HLAIACAN)
- akta.pro secondary industry
- Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)
Keywords
Where Gynica is headquartered
LocationHeadquarters
- HQ city
- Jerusalem
- HQ country
- Israel
- HQ region
- Middle East
Offices1 record
Markets served
Gynica business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Cannabis-based Therapeutics: Gynica is developing drug candidates (IntraVagS301, IntraVagS302) for endometriosis treatment. As a clinical-stage biotech company, revenue generation is anticipated through pharmaceutical product sales following regulatory approval. The company has also signed distribution agreements for CBD product lines.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels4 records
Gynica product offering
Product offeringCore offering
Gynica develops cannabis-based intra-vaginal therapeutic solutions targeting endometriosis and women's health conditions. Its core offering is the proprietary IntraVag© microencapsulation drug delivery platform, which enables controlled-release of active pharmaceutical ingredients directly to the vaginal cavity. On this platform the company is advancing two cannabinoid-based drug candidates, IntraVagS301 and IntraVagS302, designed to alleviate endometriosis symptoms by modulating the endocannabinoid system. The company also distributes a cannabinoid-based CBD product line via channel partnerships in Israel.
Product overview
Gynica is a biotech company offering a portfolio of cannabinoid-based therapeutic solutions for women's health conditions, primarily focusing on endometriosis. The company's core technology is the proprietary IntraVag© microencapsulation drug delivery platform, which enables controlled-release of active pharmaceutical ingredients directly to the vaginal cavity. Using this platform, Gynica is developing two drug candidates—IntraVagS301 and IntraVagS302—as intra-vaginal therapeutic solutions for endometriosis symptoms. The company also maintains a CBD consumer product line distributed via partnership agreements. All offerings leverage the therapeutic properties of cannabinoids targeting the endocannabinoid system to address endocannabinoid deficiency associated with endometriosis.
Differentiator
Problem solved
Functional benefit
Companies that use Gynica
Customer profileSegments2 records
Ideal customer profiles3 records
Gynica technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Gynica partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered minor and core.
- PQE GroupminorGilda D'Incerti, CEO and founder of PQE Group (global leading pharmaceutical regulations company with 34 global offices, 21 legal entities, and 2000 employees), joined Gynica's advisory board to provide expertise in pharmaceutical regulation, quality and compliance.
- HempstreetcoreStrategic partnership with Hempstreet, India's largest cannabis company, aimed to combine traditional knowledge and formulations with cutting-edge scientific and technological capabilities for cannabis-based endometriosis treatment development.
- Altman HealthcoreKey distribution agreement with Altman Health, the market leader in Israel for OTC and supplements, for distribution of Gynica's CBD product line.
- Lumir LabcorePartnership with Lumir Lab, a research and development lab focused on cannabinoids, to find cannabis-based treatment for endometriosis. Lumir Lab provides clinical investigation expertise and houses research at Hebrew University campus. Prof. Lumir Ondrej Hanus leads the research.
- Strainprint TechnologiescorePartnership with Canadian startup Strainprint Technologies to conduct the world's first international clinical study on cannabis use for endometriosis. Established world's first and largest database of medical cannabis effects on women using Strainprint's proprietary digital research platform and outcomes-tracking mobile application.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
Gynica competitors and assessment
Company assessmentBroad incumbents
- Organon & Co. Organon is a global women's health pharmaceutical company with established endometriosis franchises and deep relationships with OB/GYNs. While Organon does not focus on cannabis therapeutics, it represents a potential large-pharma acquirer and competitor for the endometriosis prescriber channel.
- AbbVie: AbbVie commercializes Orilissa (elagolix), the leading non-surgical endometriosis treatment. While not focused on cannabis therapeutics, AbbVie is a major incumbent in the endometriosis indication with established physician access, deep commercialization infrastructure, and substantially more clinical resources than Gynica.
Direct peers
- Corbus Pharmaceuticals: Corbus Pharmaceuticals develops cannabinoid-derived therapeutics, including lenabasum, with a focus on inflammatory and fibrotic diseases. Comparable as a clinical-stage cannabinoid pharmaceutical company pursuing regulator-approved prescription products.
- GW Pharmaceuticals (Jazz Pharmaceuticals): Jazz Pharmaceuticals acquired GW Pharmaceuticals, the pioneer in cannabis-derived prescription therapeutics (Epidiolex, Sativex). GW is the most direct comparable as a pharmaceutical company developing rigorously tested, regulator-approved cannabinoid-based drugs—the same regulatory and clinical pathway Gynica is pursuing.
- InMed Pharmaceuticals: InMed Pharmaceuticals develops cannabinoid-based pharmaceutical products, including therapies targeting rare diseases and women's health conditions. Directly comparable as a small clinical-stage biotech focused on prescription-grade cannabinoid therapeutics with similar regulatory pathway.
- Myovant Sciences (Pfizer): Myovant developed Myfembree (relugolix combination) for endometriosis pain, making it a direct indication peer. Although the mechanism (GnRH antagonist) differs from cannabis, both target the same patient population and compete for the same physician-prescriber relationships in endometriosis treatment.
- Botanix Pharmaceuticals: Botanix Pharmaceuticals is a clinical-stage cannabinoid therapeutics company developing prescription treatments using synthetic CBD. Comparable as a small-cap, clinical-stage pharma developing rigorously tested cannabinoid-based drugs targeting specific medical indications.
- Tikun-Olam Cannbit: Tikun-Olam Cannbit is an Israeli cannabis pharma company that is Gynica's strategic investor and pharmaceutical partner. Comparable as an Israeli-based cannabis pharmaceutical company with overlapping therapeutic focus and a direct commercial relationship.
Emerging players
- Sol-Gel Technologies: Sol-Gel Technologies (Nasdaq-traded) is a dermatology specialty pharma company where CTO Haim Barsimantov previously served as COO/CTO. Comparable as a microencapsulation-based specialty pharma company using proprietary delivery technology—a direct technology analogue to Gynica's IntraVag© platform.
Regional players
- Hempstreet: Hempstreet is India's largest retail-to-research cannabis company focused on Ayurvedic cannabis-based therapeutics for women's health. Directly comparable as a cannabis-women's health peer; Gynica has an active strategic partnership with Hempstreet covering the Indian market.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks3 records
Key highlights6 records
Customer concentration
Gynica social profiles
Digital presenceGynica financial estimates
Financial estimateRevenue estimate
Valuation estimate
Gynica leadership team
Management profileNumber of profiles
Profiles5 records
Gynica funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Gynica M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Gynica
What does Gynica do?
Gynica develops cannabis-based intra-vaginal therapeutic solutions targeting endometriosis and women's health conditions. Its core offering is the proprietary IntraVag© microencapsulation drug delivery platform, which enables controlled-release of active pharmaceutical ingredients directly to the vaginal cavity. On this platform the company is advancing two cannabinoid-based drug candidates, IntraVagS301 and IntraVagS302, designed to alleviate endometriosis symptoms by modulating the endocannabinoid system. The company also distributes a cannabinoid-based CBD product line via channel partnerships in Israel.
Is Gynica a public or private company?
Gynica is a private company. It is classified as venture growth investor backed and is currently operating.
When was Gynica founded?
Gynica was founded in 2017. It employs 1 to 10 people.
Where is Gynica based?
Gynica is headquartered in Jerusalem, Israel, in the Middle East region.
How does Gynica make money?
One revenue line is on record: cannabis-based Therapeutics.
Who are Gynica's main competitors?
Broad incumbents on record are Organon & Co. and AbbVie. Direct peers are Corbus Pharmaceuticals, GW Pharmaceuticals (Jazz Pharmaceuticals), InMed Pharmaceuticals, Myovant Sciences (Pfizer), Botanix Pharmaceuticals and Tikun-Olam Cannbit. Sol-Gel Technologies is listed as an emerging player. Hempstreet is listed as a regional player.
Does Gynica have an API?
No public API is recorded for Gynica.
What industry is Gynica in?
Gynica's product category is Women's Health Biotechnology. Its primary akta.pro industry code is HLAIACAN, Women’s Health & Reproductive Specialty Pharmaceuticals, with a secondary code of HLAIAAAJ, Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health). Its NAICS code is 325412 and its SIC code is 2834.